5004-88-6

Usage

Uses

Used in Pharmaceutical Research:
2-AMINO-4,5-DIMETHOXYBENZAMIDE is used as an active pharmaceutical ingredient for the development of new drugs, leveraging its antifungal, antibacterial, and potential anticancer properties.
Used in Organic Synthesis:
2-AMINO-4,5-DIMETHOXYBENZAMIDE is used as a key intermediate in the synthesis of various organic compounds, contributing to the advancement of chemical research and the creation of novel materials.
Used in Anticancer Applications:
2-AMINO-4,5-DIMETHOXYBENZAMIDE is studied for its potential use as an anticancer agent, with ongoing research exploring its ability to target and inhibit the growth of cancer cells.
Used in Antifungal and Antibacterial Applications:
2-AMINO-4,5-DIMETHOXYBENZAMIDE is used as an antimicrobial agent in various applications, such as in the development of new antibiotics and antifungal medications, to combat resistant strains and improve treatment options.
Used in Antioxidant and Anti-inflammatory Applications:
2-AMINO-4,5-DIMETHOXYBENZAMIDE is utilized for its antioxidant and anti-inflammatory activities, which can be applied in the development of treatments for various inflammatory and oxidative stress-related conditions.

InChI:InChI=1/C9H12N2O3/c1-13-7-3-5(9(11)12)6(10)4-8(7)14-2/h3-4H,10H2,1-2H3,(H2,11,12)

Upstream product

• 4959-60-8 4,5-dimethoxy-2-nitrobenzamide 
• 530-62-1 1,1'-carbonyldiimidazole 
• 5653-40-7 2-Amino-4,5-dimethoxybenzoic acid 
• 13794-72-4 3H-6,7-dimethoxyquinazolin-4-one 
• 1092075-61-0 2-amino-4,5-dimethoxy-N,N-bis[(5-methyl-2-furyl)methyl]benzamide 
• 1397833-86-1 (2-amino-4,5-dimethoxyphenyl)(benzotriazole-1-yl)methanone 
• 29568-78-3 4,5-dimethoxy-2-nitrobenzoyl chloride 
• 4998-07-6 4,5-dimethoxy-2-nitro-benzoic acid 

Downstream Products

• 105189-30-8 6,7-Dimethoxy-2-[3-(3-piperidin-1-ylmethyl-phenoxy)-propyl]-3H-quinazolin-4-one 
• 13794-72-4 3H-6,7-dimethoxyquinazolin-4-one 
• 334025-80-8 4,5-Dimethoxy-2-(4-methylamino-benzoylamino)-benzamide 
• 334025-78-4 4,5-dimethoxy-2-(4-nitrobenzamido)benzamide 
• 202475-60-3 WHI-P₁₃₁ 
• 211555-04-3 4-(3-bromo-4-hydroxyphenyl)amino-6,7-dimethoxyquinazoline 
• 334025-79-5 2-(4-aminophenyl)-carbonylamino-4,5-dimethoxybenzamide 
• 314769-05-6 2-(3'-Methoxyphenyl)-6,7-dimethoxy-4-quinazolinone 
• 228118-55-6 2-((4-chlorophenyl)carbonylamino)-4,5-dimethoxybenzamide 
• 1370974-73-4 N-(2-carbamoyl-4,5-dimethoxyphenyl)-[1,1'-biphenyl]-4-carboxamide 
• 1024582-84-0 4,5-dimethoxy-2-(3-nitrobenzoyl)aminobenzamide 
• 911417-97-5 C₂₂H₁₉FN₂O₄ 
• 1044870-76-9 2-(4-hydroxy-3,5-dimethylphenyl)-6,7-dimethoxyquinazolin-4(3H)-one 

Relevant academic research and scientific papers

Scaffold hopping and optimisation of 3’,4’-dihydroxyphenyl- containing thienopyrimidinones: synthesis of quinazolinone derivatives as novel allosteric inhibitors of HIV-1 reverse transcriptase-associated ribonuclease H

Bioisosteric replacement and scaffold hopping are powerful strategies in drug design useful for rationally modifying a hit compound towards novel lead therapeutic agents. Recently, we reported a series of thienopyrimidinones that compromise dynamics at the p66/p51 HIV-1 reverse transcriptase (RT)-associated Ribonuclease H (RNase H) dimer interface, thereby allosterically interrupting catalysis by altering the active site geometry. Although they exhibited good submicromolar activity, the isosteric replacement of the thiophene ring, a potential toxicophore, is warranted. Thus, in this article, the most active 2-(3,4-dihydroxyphenyl)-5,6-dimethylthieno[2,3-d]pyrimidin-4(3H)-one 1 was selected as the hit scaffold and several isosteric substitutions of the thiophene ring were performed. A novel series of highly active RNase H allosteric quinazolinone inhibitors was thus obtained. To determine their target selectivity, they were tested against RT-associated RNA-dependent DNA polymerase (RDDP) and integrase (IN). Interestingly, none of the compounds were particularly active on (RDDP) but many displayed micromolar to submicromolar activity against IN.

ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF

Disclosed herein are methods and compounds of augmenting and enhancing the production of type I IFNs in vivo. In some embodiments, the compounds disclosed herein are ENPP-1 inhibitors, pharmaceutical compositions, and methods for the treatment of cancer or a viral infection.

Anthranilamide-based 2-phenylcyclopropane-1-carboxamides, 1,1'-biphenyl-4-carboxamides and 1,1'-biphenyl-2-carboxamides: Synthesis biological evaluation and mechanism of action

Several anthranilamide-based 2-phenylcyclopropane-1-carboxamides 13a-f, 1,1’-biphenyl-4-carboxamides 14a-f and 1,1’-biphenyl-2-carboxamides 17a-f were obtained by a multistep procedure starting from the (1S,2S)-2-phenylcyclopropane-1-carbonyl chloride 11, the 1,1'-biphenyl-4-carbonyl chloride 12 or the 1,1'-biphenyl-2-carbonyl chloride 16 with the appropriate anthranilamide derivative 10a-f. Derivatives 13a-f, 14a-f and 17a-f showed antiproliferative activity against human leukemia K562?cells. Among these derivatives 13b, 14b and 17b exerted a particular cytotoxic effect on tumor cells. Derivative 17b showed a better antitumoral effect on K562?cells than 13b and 14b. Analyses performed to explore 17b mode of action revealed that it induced an arrest in G2/M phase of cell cycle which was consequent to DNA lesions as demonstrated by the increase in phospho-ATM and γH2AX, two known markers of DNA repair response system. The effect of 17b was also related to ROS generation, activation of JNK and induction of caspase-3 dependent apoptosis.

Synthesis, antiproliferative activity and possible mechanism of action of novel 2-acetamidobenzamides bearing the 2-phenoxy functionality

Several new 2-(2-phenoxyacetamido)benzamides 17a-v, 21 and 22 were synthesized by stirring in pyridine the acid chlorides 16a-e and the appropriate5-R-4-R1-2-aminobenzamide 15a-e and initially evaluated in vitro for antiproliferative activity against the K562 (human chronic myelogenous leukemia) cell line. Some of synthesized compounds were evaluated for their in vitro antiproliferative activity against the full NCI tumor cell line panel derived from nine clinically isolated cancer types (leukemia, non-small cell lung, colon, CNS, melanoma, ovarian, renal, prostate and breast). The most active compounds caused an arrest of K562 cells in the G0-G1 phase of cell cycle and induction of apoptosis, which was mediated by caspase activation.

TETRAHYDROISOQUINOLIN-2-YL-(QUINAZOLIN-4-YL) METHANONE COMPOUNDS AS CANCER CELL GROWTH INHIBITORS

Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone derivatives represented by formula (I), pharmacologically acceptable salts thereof, and compositions containing such compounds are described. Methods for treating hyperproliferative disorders by administering the compounds are also described. 1,2,3,4-tetrahydroisoquinoline derivatives for making tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone compounds are also described.

TREATMENT OF DISEASES BY EPIGENETIC REGULATION

The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (BET) proteins. The disclosed compositions and methods can be used for treatment and prevention of cancer, including NUT midline carcinoma, Burkitt's Lymphoma, Acute Myelogenous Leukemia, and Multiple Myeloma; autoimmune or inflammatory diseases or conditions, and sepsis.

Design and synthesis of 6,7-dimethoxyquinazoline analogs as multi-targeted ligands for α1- and AII-receptors antagonism

Multiple-targeted ligands can have certain advantages for the management of hypertension which has multiple controls. Molecules with dual bioactivities are available in literature for treating metabolic disorders like diabetes, hypertension and hypercholesterolemia. After scrutinizing the SAR of prazosin-type α1-blockers and AII-antagonists it was planned to develop dual α1- and AII-antagonists. Five series of quinazoline derivatives were synthesized and evaluated as dual α1- and AII-antagonists on rat aortic strips for the blockade of known α1- and AII-agonist mediated contractions. Many compounds showed balanced activity on both the receptors but compound (22) was found to be the most active derivative having higher antagonistic activity on both the receptors. In the in vivo experiments the chosen compound (22) was slightly less active than prazosin but was found to be equipotent to losartan. These findings shed a new light on the structural requirements for both α1- as well as AII-receptor antagonists.

2-Cinnamamido, 2-(3-phenylpropiolamido), and 2-(3-phenylpropanamido) benzamides: Synthesis, antiproliferativeactivity, and mechanism of action

Several new benzamides 4a-q were synthesized by stirring in pyridine the acid chlorides 3a-q with the appropriate anthranilamide derivatives 2a-g. Some of the synthesized compounds were evaluated for their in vitro antiproliferative activity against a panel of 5 human cell lines (K562 human chronic myelogenous leukemia cells, MCF-7 breast cancer cells, HTC-116 and HT26 colon cancer cells and NCI H460 non-small cell lung cancer cells).

A new protocol for the synthesis of primary, secondary and tertiary anthranilamides utilizing N-(2-aminoarylacyl)benzotriazoles

A convenient route for efficient conversion of unprotected anthranilic acids into the corresponding N-(2-aminoarylacyl)benzotrazoles is described. N-(2-Aminoarylacyl)-benzotrazoles have been successfully used to synthesize primary, secondary and tertiary anthranilamides in high yields (71-96%). ARKAT-USA, Inc.

RHO KINASE INHIBITORS

The present invention relates to inhibitors of ROCK1 and ROCK2, which may be selective for ROCK2, and methods of modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. Also provided are methods of inhibiting ROCK1 and/or ROCK2. Also provided are treatments combining inhibitors of ROCK1 and/or ROCK2 with statins.